

## [Amoxicillin + clavulanic acid](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics](#)

ATC codes: [J01CR02](#)

EMLc

Indication

Bacterial infection of unspecified site ICD11 code: [1C81](#)

INN

Amoxicillin + clavulanic acid

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Formulations

**Oral > Liquid:** 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) ; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc)

**Oral > Solid > tablet:** 500 mg (as trihydrate) + 125 mg (as potassium salt)

EML status history

First added in 1997 ([TRS 882](#))

Changed in 2002 ([TRS 914](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Removed in 2017 ([TRS 1006](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Amoxicillin + clavulanic acid](#)

DrugBank

[Amoxicillin](#),

[Clavulanic acid \(Clavulanate\)](#)

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of antibacterials undertaken by the Expert Committee in 2017, listing of amoxicillin + clavulanic acid was reviewed and specific indications for its use were recommended. Refer to the 2017 recommendation(s) for amoxicillin + clavulanic acid for more information.